Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Senate Draft Bill Compromises On Profit Incentive For Humanitarian Devices

This article was originally published in The Gray Sheet

Executive Summary

More devices approved under a humanitarian device exemption could be priced for profit if draft Senate language is enacted, but restrictions are included to ensure that current pediatric incentives are not gutted.

You may also be interested in...

Medtech-Supporter Sen. Al Franken To Resign, After Harassment Charges

Sen. Al Franken, D-Minn., who has championed key device regulatory reform changes favoring the medtech industry that are now law, will step down from his post, following newly revealed charges of sexual harassment by a former congressional staffer in 2006.

Fireworks Kept At Bay As Congress Pushes To Enact FDA Reforms By July 4

Bipartisan FDA user fee reauthorization and reform legislation sailed unanimously through the House Energy and Commerce Committee May 10, with many similarities to a Senate version that has also passed out of committee.

Negotiations Continue On Pediatric Device Reauthorization Provisions

Lawmakers in the House and Senate are still hammering out language to allow companies to continue to profit on humanitarian device exemptions with pediatric indications, and to reauthorize a grant program for non-profit pediatric device consortia.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts